SCHEMBL1067932

SCHEMBL1067932

CCOC(=O)/C=C(\CBr)Oc1ccccc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.39
ATM Q13315 1/20 0.39
RAB9A P51151 2/20 0.37
MAPT P10636 4/20 0.37
LMNA P02545 3/20 0.37
ALDH1A1 P00352 2/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 3/20 0.37
POLB P06746 2/20 0.37
KMT2A Q03164 2/20 0.37
GAA P10253 1/20 0.37
DHODH Q02127 1/20 0.37
MEN1 O00255 1/20 0.37
PLIN1 O60240 1/20 0.37
PLIN5 Q00G26 1/20 0.37
ABHD5 Q8WTS1 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1067938 1.00 TDP1 (0.42) TDP1L3MBTL1ATMRAB9AMAPT
SCHEMBL1067937 1.00 TDP1 (0.42) TDP1L3MBTL1ATMRAB9AMAPT
SCHEMBL1067862 0.89 POLB (0.42) TDP1L3MBTL1RAB9AMAPTLMNA
SCHEMBL1067867 0.89 POLB (0.42) TDP1L3MBTL1RAB9AMAPTLMNA
SCHEMBL1067865 0.89 POLB (0.42) TDP1L3MBTL1RAB9AMAPTLMNA
SCHEMBL1069056 0.87 RAB9A (0.36) L3MBTL1ATMRAB9AMAPTLMNA
SCHEMBL1066881 0.87 L3MBTL1 (0.45) TDP1L3MBTL1RAB9AMAPTLMNA
SCHEMBL1066274 0.87 MAPT (0.45) L3MBTL1RAB9AMAPTLMNAALDH1A1
SCHEMBL1069125 0.87 RAB9A (0.36) L3MBTL1ATMRAB9AMAPTLMNA
SCHEMBL1069122 0.87 RAB9A (0.36) L3MBTL1ATMRAB9AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 TDP1 1793/4885L3MBTL1 4431/4885ATM 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.